621 related articles for article (PubMed ID: 19747140)
1. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Yewale C; Baradia D; Vhora I; Patil S; Misra A
Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with monoclonal antibodies to epidermal growth factor receptor.
Calvo E; Rowinsky EK
Curr Oncol Rep; 2005 Mar; 7(2):96-103. PubMed ID: 15717942
[TBL] [Abstract][Full Text] [Related]
5. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives.
Zhu Z
Acta Pharmacol Sin; 2007 Sep; 28(9):1476-93. PubMed ID: 17723181
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor inhibition strategies in oncology.
Harari PM
Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
[TBL] [Abstract][Full Text] [Related]
7. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.
Niesen J; Stein C; Brehm H; Hehmann-Titt G; Fendel R; Melmer G; Fischer R; Barth S
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2079-95. PubMed ID: 25899161
[TBL] [Abstract][Full Text] [Related]
8. A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today's patients.
Jackson C; Cunningham D
Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S8-15. PubMed ID: 18361806
[TBL] [Abstract][Full Text] [Related]
9. EGFR targeting of solid tumors.
Rocha-Lima CM; Soares HP; Raez LE; Singal R
Cancer Control; 2007 Jul; 14(3):295-304. PubMed ID: 17615536
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor inhibition in solid tumours.
Ganti AK; Potti A
Expert Opin Biol Ther; 2005 Sep; 5(9):1165-74. PubMed ID: 16120047
[TBL] [Abstract][Full Text] [Related]
11. EGFR-targeting monoclonal antibodies in head and neck cancer.
Astsaturov I; Cohen RB; Harari PM
Curr Cancer Drug Targets; 2006 Dec; 6(8):691-710. PubMed ID: 17168674
[TBL] [Abstract][Full Text] [Related]
12. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer.
Snyder LC; Astsaturov I; Weiner LM
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S71-80. PubMed ID: 16336752
[TBL] [Abstract][Full Text] [Related]
13. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S42-6. PubMed ID: 18021486
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab: from bench to bedside.
Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
[TBL] [Abstract][Full Text] [Related]
15. Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors.
Argyriou AA; Kalofonos HP
Mol Med; 2009; 15(5-6):183-91. PubMed ID: 19305491
[TBL] [Abstract][Full Text] [Related]
16. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
18. Extending outcomes: epidermal growth factor receptor-targeted monoclonal antibodies in non-small-cell lung cancer.
Joy AA; Butts CA
Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S24-9. PubMed ID: 19362943
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor as a target for chemotherapy.
Vallbohmer D; Lenz HJ
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S19-27. PubMed ID: 15871762
[TBL] [Abstract][Full Text] [Related]
20. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
